Dopamine D2 and adenosine A2A receptors regulate NMDA-mediated excitation in accumbens neurons through A2A-D2 receptor heteromerization.
Bursting activity of striatal medium spiny neurons results from membrane potential oscillations between a down- and an upstate that could be regulated by G-protein-coupled receptors. Among these, dopamine D(2) and adenosine A(2A) receptors are highly enriched in striatal neurons and exhibit strong interactions whose physiological significance and molecular mechanisms remain partially unclear. More particularly, respective involvements of common intracellular signaling cascades and A(2A)-D(2) receptor heteromerization remain unknown. Here we show, by performing perforated-patch-clamp recordings on brain slices and loading competitive peptides, that D(2) and A(2A) receptors regulate the induction by N-methyl-D-aspartate of a depolarized membrane potential plateau through mechanisms relying upon specific protein-protein interactions. Indeed, D(2) receptor activation abolished transitions between a hyperpolarized resting potential and a depolarized plateau potential by regulating the Ca(V)1.3a calcium channel activity through interactions with scaffold proteins Shank1/3. Noticeably, A(2A) receptor activation had no effect per se but fully reversed the effects of D(2) receptor activation through a mechanism in which A(2A)-D(2) receptors heteromerization is strictly mandatory, demonstrating therefore a first direct physiological relevance of these heteromers. Our results show that membrane potential transitions and firing patterns in striatal neurons are tightly controlled by D(2) and A(2A) receptors through specific protein-protein interactions including A(2A)-D(2) receptors heteromerization.
Azdad
Karima
K
Laboratory of Neurophysiology, Université Libre de Bruxelles, Brussels, Belgium. kazdad@ulb.ac.be
Gall
David
D
Woods
Amina S
AS
Ledent
Catherine
C
Ferré
Sergi
S
Schiffmann
Serge N
SN
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism; D000818:Animals; D020746:Calcium Channels, L-Type / Q000378:metabolism; D066298:In Vitro Techniques; D008564:Membrane Potentials / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D016202:N-Methylaspartate / Q000378:metabolism*; D009419:Nerve Tissue Proteins; D009474:Neurons / Q000378:metabolism*; D009714:Nucleus Accumbens / Q000166:cytology / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D017729:Presynaptic Terminals / Q000378:metabolism; D055503:Protein Multimerization; D051381:Rats; D017208:Rats, Wistar; D043683:Receptors, Adenosine A2 / Q000378:metabolism*; D017448:Receptors, Dopamine D2 / Q000378:metabolism*
D048868:Adaptor Proteins, Signal Transducing; D020746:Calcium Channels, L-Type; D009419:Nerve Tissue Proteins; D043683:Receptors, Adenosine A2; D017448:Receptors, Dopamine D2; C120531:Shank1 protein, rat; C120532:Shank3 protein, rat; D016202:N-Methylaspartate
J Biol Chem. 2003 Nov 21;278(47):46741-9
12933819
Neuron. 2006 May 4;50(3):443-52
16675398
J Neurosci. 2001 Aug 15;21(16):5944-51
11487617
J Neurosci. 1995 May;15(5 Pt 1):3622-39
7751934
J Neurosci. 2000 Dec 15;20(24):8987-95
11124974
J Physiol. 2003 Nov 15;553(Pt 1):169-82
12963790
Eur J Neurosci. 2004 May;19(9):2455-63
15128399
J Biol Chem. 2001 Jun 22;276(25):22100-6
11285265
Biochem Pharmacol. 1999 Sep 15;58(6):1035-45
10509756
J Gen Physiol. 1988 Aug;92(2):145-59
2459299
Eur J Neurosci. 2000 Nov;12(11):4033-7
11069599
Nature. 2003 Oct 30;425(6961):917-25
14586460
Life Sci. 1984 Dec 3;35(23):2281-96
6390056
Annu Rev Neurosci. 2000;23:185-215
10845063
Pharmacol Rev. 2003 Sep;55(3):509-50
12869660
J Neurosci. 1993 Dec;13(12):5402-6
8254382
Curr Opin Pharmacol. 2002 Oct;2(5):581-6
12324263
J Neurosci. 1996 Apr 1;16(7):2397-410
8601819
J Neurosci. 2002 Jan 1;22(1):294-304
11756513
Amino Acids. 1998;14(1-3):33-9
9871438
Neurology. 2003 Dec 9;61(11 Suppl 6):S12-8
14663003
Nature. 1994 Mar 17;368(6468):242-6
7908412
J Neurochem. 2000 Jan;74(1):432-9
10617149
Trends Neurosci. 2007 May;30(5):228-35
17408758
J Neurochem. 1991 Sep;57(3):1062-7
1713612
J Neurosci. 2003 Jun 15;23(12):5079-87
12832531
Nature. 1997 Aug 14;388(6643):674-8
9262401
Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7238-41
1678519
Anal Chem. 2004 Sep 15;76(18):5354-63
15362892
Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2123-30
15615842
J Physiol. 1995 Apr 15;484 ( Pt 2):397-413
7602534
Nature. 1998 Jul 30;394(6692):475-8
9697769
Proc Natl Acad Sci U S A. 1985 Feb;82(3):737-41
2983313
Eur J Pharmacol. 2005 Sep 27;520(1-3):43-50
16137674
J Neurosci. 2001 Jun 15;21(12):4498-504
11404437
Cereb Cortex. 2007 May;17(5):1235-40
16818475
J Neurosci. 2007 Jun 20;27(25):6781-7
17581965
J Neurosci. 1995 Jul;15(7 Pt 2):5222-37
7623147
J Neurosci. 1993 Mar;13(3):1080-7
7680065
J Biol Chem. 2002 May 17;277(20):18091-7
11872740
J Neurosci. 2005 Feb 2;25(5):1050-62
15689540
Prog Neurobiol. 2007 Dec;83(5):277-92
17646043
Neuron. 1995 Feb;14(2):385-97
7531987
J Proteome Res. 2005 Jul-Aug;4(4):1397-402
16083292
Neuroscience. 2001;107(3):455-64
11719000
Proc Natl Acad Sci U S A. 1978 Jan;75(1):248-51
203933
Drug Discov Today. 2006 Jun;11(11-12):541-9
16713906
Trends Neurosci. 2000 Oct;23(10 Suppl):S48-56
11052220
J Mol Neurosci. 2005;26(2-3):277-92
16012201
Trends Neurosci. 1997 Oct;20(10):482-7
9347617
Curr Opin Neurobiol. 2000 Jun;10 (3):370-4
10851183
Eur J Pharmacol. 1996 Dec 5;316(2-3):325-31
8982704
Trends Neurosci. 1990 Jul;13(7):266-71
1695401
J Neurosci. 1997 May 1;17(9):3334-42
9096166
Science. 1990 Dec 7;250(4986):1429-32
2147780
Nat Rev Neurosci. 2004 Oct;5(10):771-81
15378037
J Neurosci. 2003 Oct 15;23(28):9320-7
14561859
Prog Neurobiol. 1999 Nov;59(4):355-96
10501634
Biochem J. 2005 Oct 15;391(Pt 2):417-24
15975091
J Neurosci. 2005 Feb 2;25(5):1037-49
15689539
J Physiol. 1989 Jul;414:265-82
2607432
Eur J Biochem. 2000 Jan;267(2):337-43
10632703